Financhill
Sell
40

HCM Quote, Financials, Valuation and Earnings

Last price:
$16.19
Seasonality move :
1.51%
Day range:
$15.95 - $16.16
52-week range:
$11.51 - $21.50
Dividend yield:
0%
P/E ratio:
78.45x
P/S ratio:
4.44x
P/B ratio:
3.61x
Volume:
28.6K
Avg. volume:
90K
1-year change:
-9.79%
Market cap:
$2.7B
Revenue:
$630.2M
EPS (TTM):
$0.20

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HCM
HUTCHMED (China)
-- -- -- -- $23.97
BLTE
Belite Bio
-- -$0.42 -- -25.81% $93.75
HKPD
Hong Kong Pharma Digital Technology Holdings
-- -- -- -- --
PRE
Prenetics Global
$21.7M -- 265.23% -- $14.00
RGC
Regencell Bioscience Holdings
-- -- -- -- --
SBMFF
Sino Biopharmaceutical
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HCM
HUTCHMED (China)
$16.04 $23.97 $2.7B 78.45x $0.00 0% 4.44x
BLTE
Belite Bio
$63.22 $93.75 $2.1B -- $0.00 0% --
HKPD
Hong Kong Pharma Digital Technology Holdings
$1.36 -- $14.9M 8.18x $0.00 0% 0.75x
PRE
Prenetics Global
$7.89 $14.00 $102.8M -- $0.00 0% 2.41x
RGC
Regencell Bioscience Holdings
$14.75 -- $7.3B -- $0.00 0% --
SBMFF
Sino Biopharmaceutical
$0.71 -- $12.7B 25.66x $0.01 1.26% 3.24x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HCM
HUTCHMED (China)
9.83% 0.273 3.34% 2.67x
BLTE
Belite Bio
-- -1.670 -- --
HKPD
Hong Kong Pharma Digital Technology Holdings
-- 0.000 -- --
PRE
Prenetics Global
-- 1.761 -- 1.85x
RGC
Regencell Bioscience Holdings
-- 17.002 -- --
SBMFF
Sino Biopharmaceutical
23.1% 0.188 14.66% 1.14x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HCM
HUTCHMED (China)
-- -- 4.51% 4.99% -- --
BLTE
Belite Bio
-- -$15.5M -- -- -- --
HKPD
Hong Kong Pharma Digital Technology Holdings
-- -- -- -- -- --
PRE
Prenetics Global
$7.3M -$10.9M -26.55% -26.55% -63.56% --
RGC
Regencell Bioscience Holdings
-- -- -- -- -- --
SBMFF
Sino Biopharmaceutical
-- -- 6.83% 8.57% -- --

HUTCHMED (China) vs. Competitors

  • Which has Higher Returns HCM or BLTE?

    Belite Bio has a net margin of -- compared to HUTCHMED (China)'s net margin of --. HUTCHMED (China)'s return on equity of 4.99% beat Belite Bio's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HCM
    HUTCHMED (China)
    -- -- $854.7M
    BLTE
    Belite Bio
    -- -$0.45 --
  • What do Analysts Say About HCM or BLTE?

    HUTCHMED (China) has a consensus price target of $23.97, signalling upside risk potential of 50.94%. On the other hand Belite Bio has an analysts' consensus of $93.75 which suggests that it could grow by 48.29%. Given that HUTCHMED (China) has higher upside potential than Belite Bio, analysts believe HUTCHMED (China) is more attractive than Belite Bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    HCM
    HUTCHMED (China)
    9 3 0
    BLTE
    Belite Bio
    3 0 0
  • Is HCM or BLTE More Risky?

    HUTCHMED (China) has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison Belite Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HCM or BLTE?

    HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Belite Bio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HCM or BLTE?

    HUTCHMED (China) quarterly revenues are --, which are smaller than Belite Bio quarterly revenues of --. HUTCHMED (China)'s net income of -- is lower than Belite Bio's net income of -$14.3M. Notably, HUTCHMED (China)'s price-to-earnings ratio is 78.45x while Belite Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 4.44x versus -- for Belite Bio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCM
    HUTCHMED (China)
    4.44x 78.45x -- --
    BLTE
    Belite Bio
    -- -- -- -$14.3M
  • Which has Higher Returns HCM or HKPD?

    Hong Kong Pharma Digital Technology Holdings has a net margin of -- compared to HUTCHMED (China)'s net margin of --. HUTCHMED (China)'s return on equity of 4.99% beat Hong Kong Pharma Digital Technology Holdings's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HCM
    HUTCHMED (China)
    -- -- $854.7M
    HKPD
    Hong Kong Pharma Digital Technology Holdings
    -- -- --
  • What do Analysts Say About HCM or HKPD?

    HUTCHMED (China) has a consensus price target of $23.97, signalling upside risk potential of 50.94%. On the other hand Hong Kong Pharma Digital Technology Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe HUTCHMED (China) is more attractive than Hong Kong Pharma Digital Technology Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    HCM
    HUTCHMED (China)
    9 3 0
    HKPD
    Hong Kong Pharma Digital Technology Holdings
    0 0 0
  • Is HCM or HKPD More Risky?

    HUTCHMED (China) has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HCM or HKPD?

    HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hong Kong Pharma Digital Technology Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HCM or HKPD?

    HUTCHMED (China) quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings quarterly revenues of --. HUTCHMED (China)'s net income of -- is lower than Hong Kong Pharma Digital Technology Holdings's net income of --. Notably, HUTCHMED (China)'s price-to-earnings ratio is 78.45x while Hong Kong Pharma Digital Technology Holdings's PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 4.44x versus 0.75x for Hong Kong Pharma Digital Technology Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCM
    HUTCHMED (China)
    4.44x 78.45x -- --
    HKPD
    Hong Kong Pharma Digital Technology Holdings
    0.75x 8.18x -- --
  • Which has Higher Returns HCM or PRE?

    Prenetics Global has a net margin of -- compared to HUTCHMED (China)'s net margin of -60.02%. HUTCHMED (China)'s return on equity of 4.99% beat Prenetics Global's return on equity of -26.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    HCM
    HUTCHMED (China)
    -- -- $854.7M
    PRE
    Prenetics Global
    42.41% -$0.80 $161.1M
  • What do Analysts Say About HCM or PRE?

    HUTCHMED (China) has a consensus price target of $23.97, signalling upside risk potential of 50.94%. On the other hand Prenetics Global has an analysts' consensus of $14.00 which suggests that it could grow by 77.44%. Given that Prenetics Global has higher upside potential than HUTCHMED (China), analysts believe Prenetics Global is more attractive than HUTCHMED (China).

    Company Buy Ratings Hold Ratings Sell Ratings
    HCM
    HUTCHMED (China)
    9 3 0
    PRE
    Prenetics Global
    1 0 0
  • Is HCM or PRE More Risky?

    HUTCHMED (China) has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HCM or PRE?

    HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HCM or PRE?

    HUTCHMED (China) quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $17.3M. HUTCHMED (China)'s net income of -- is lower than Prenetics Global's net income of -$10.4M. Notably, HUTCHMED (China)'s price-to-earnings ratio is 78.45x while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 4.44x versus 2.41x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCM
    HUTCHMED (China)
    4.44x 78.45x -- --
    PRE
    Prenetics Global
    2.41x -- $17.3M -$10.4M
  • Which has Higher Returns HCM or RGC?

    Regencell Bioscience Holdings has a net margin of -- compared to HUTCHMED (China)'s net margin of --. HUTCHMED (China)'s return on equity of 4.99% beat Regencell Bioscience Holdings's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HCM
    HUTCHMED (China)
    -- -- $854.7M
    RGC
    Regencell Bioscience Holdings
    -- -- --
  • What do Analysts Say About HCM or RGC?

    HUTCHMED (China) has a consensus price target of $23.97, signalling upside risk potential of 50.94%. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) has higher upside potential than Regencell Bioscience Holdings, analysts believe HUTCHMED (China) is more attractive than Regencell Bioscience Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    HCM
    HUTCHMED (China)
    9 3 0
    RGC
    Regencell Bioscience Holdings
    0 0 0
  • Is HCM or RGC More Risky?

    HUTCHMED (China) has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HCM or RGC?

    HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HCM or RGC?

    HUTCHMED (China) quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. HUTCHMED (China)'s net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, HUTCHMED (China)'s price-to-earnings ratio is 78.45x while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 4.44x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCM
    HUTCHMED (China)
    4.44x 78.45x -- --
    RGC
    Regencell Bioscience Holdings
    -- -- -- --
  • Which has Higher Returns HCM or SBMFF?

    Sino Biopharmaceutical has a net margin of -- compared to HUTCHMED (China)'s net margin of --. HUTCHMED (China)'s return on equity of 4.99% beat Sino Biopharmaceutical's return on equity of 8.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    HCM
    HUTCHMED (China)
    -- -- $854.7M
    SBMFF
    Sino Biopharmaceutical
    -- -- $7.2B
  • What do Analysts Say About HCM or SBMFF?

    HUTCHMED (China) has a consensus price target of $23.97, signalling upside risk potential of 50.94%. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) has higher upside potential than Sino Biopharmaceutical, analysts believe HUTCHMED (China) is more attractive than Sino Biopharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    HCM
    HUTCHMED (China)
    9 3 0
    SBMFF
    Sino Biopharmaceutical
    0 0 0
  • Is HCM or SBMFF More Risky?

    HUTCHMED (China) has a beta of 0.522, which suggesting that the stock is 47.848% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.585, suggesting its less volatile than the S&P 500 by 41.522%.

  • Which is a Better Dividend Stock HCM or SBMFF?

    HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical offers a yield of 1.26% to investors and pays a quarterly dividend of $0.01 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out 52.76% of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios HCM or SBMFF?

    HUTCHMED (China) quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. HUTCHMED (China)'s net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, HUTCHMED (China)'s price-to-earnings ratio is 78.45x while Sino Biopharmaceutical's PE ratio is 25.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 4.44x versus 3.24x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCM
    HUTCHMED (China)
    4.44x 78.45x -- --
    SBMFF
    Sino Biopharmaceutical
    3.24x 25.66x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 14

MiNK Therapeutics [INKT] is down 36.03% over the past day.

Buy
51
NEGG alert for Jul 14

Newegg Commerce [NEGG] is down 26.42% over the past day.

Buy
68
ATRO alert for Jul 14

Astronics [ATRO] is down 1.02% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock